◆ 会议时间：2024年9月19-22日
◆ 会议地点：西班牙 巴塞罗那

◆ 会议简介：

2024年第24届欧洲视网膜专家学会(EURETINA)大会/年会将于2024年9月19-22日在西班牙巴塞罗那举行，预计有来自世界各地的5000余名专业人士与会。

欧洲视网膜专家学会(EURETINA)成立于1999年，由对治疗黄斑以及玻璃体视网膜疾病感兴趣的临床医生、科学家和研究者组成。EURETINA的宗旨是促进欧洲玻璃体视网膜和黄斑专家之间的知识交流并建立个人联系；支持和促进欧洲在玻璃体视网膜和黄斑方面的研究；将相关专业知识传播给普通眼科医师；与欧洲之外的类似相关团体保持联系。未经许可禁止复制摘录转载本站任何内容-国际医学会议网（lingyuint.com）

24th Congress of the European Society of Retina Specialists (EURETINA2024)

时间/Date:
19-22 September 2024

会场/Venue:
CCIB, Barcelona, Spain

摘要征文投稿：

Submit your Free Paper, e-Poster & Video Abstracts today.  

Submissions Deadline: Monday 18th March (23:59 CET)

点此提交摘要>>>Submit Abstract>>>

Terms & Conditions

– The Free Paper submission portal opens Monday 22nd January and will be closing Monday 18th March (23:59 CET).

– Please note that you must be an EURETINA Member in order to submit a Free Paper abstract. If you are not a member please CLICK HERE to join. 

– Presenting authors must be ophthalmologists.

– Co-authors must be ophthalmologists, other healthcare professionals or researchers that have contributed to the project.

– Free Paper abstracts will be considered for 5-minute presentation slots in Free Paper Sessions OR as Audio Narrated Free Papers available online and on designated computer terminals in the Congress centre, depending on review outcome.

– Each applicant may submit a maximum of 2 Free Paper abstracts.

– If you wish to withdraw your accepted abstract from the Congress programme, you must confirm via email to programme@euretina.org by Thursday 5th September, 2024 (23:59 CET).

If you choose to submit an abstract(s) we will use your personal details to keep you updated on its status including whether it has been accepted for presentation at the Euretina Congress. If your abstract(s) is accepted for presentation at the Euretina Congress your contact details (name and email address) will be sent to a third-party Audio-Visual Company in order for them to contact you in relation to uploading your presentation.

Review & Evaluation

– All submitted abstracts will be reviewed before a final selection is made.

– Specific topics that need to be covered in the Congress programme will be considered before making the final selection of accepted abstracts. The decision of the Euretina Review Committee is final.

– If your abstract is accepted, you will be informed of this by email by the end of June, 2024. 

– It is not possible to reschedule the assigned time of an accepted Free Paper.

Abstract Submission

All submitted abstracts must be in English and follow the structured format below:

– Title (250 characters max)

– Purpose (100 words max)

– Setting/Venue (50 words max)

– Methods (200 words max)

– Results (200 words max)

– Conclusions (200 words max)

All abstracts MUST be submitted in the presenting author’s name.

Financial Disclosure: Please indicate Yes/No. If applicable please clearly list your financial interest in the subject matter or if you receive funds from any mentioned companies.

Further Instructions

– Presentations titles must not include company names.

– Accepted presentations must not include company branded slides.

– The summary of results presented must be given in sufficient detail to support the conclusions. The Review Committee will only accept abstracts with final results or conclusions.

– Formulae should, in general, be avoided.

– When using abbreviations or acronyms for the first time, care should be taken to spell them out in full with the abbreviation in parentheses after the full word(s) the first time it appears in the text. The abbreviation should be used alone thereafter.

– There is an embargo on oral presentations until the first day of the annual Congress programme.

– Euretina does not take any ownership of the copyright of a presentation. However, presenters are required to sign a Transfer of Rights document at the time of the presentation upload.

– Accepted presentations will be displayed on EURETINA On Demand after the Congress.

25th EURETINA Congress
4-7 September 2025
Le Palais des Congres, Paris, France

◆ 参会对象：医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。